Skip to main
GPCR
GPCR logo

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics Inc presents a positive outlook due to the promising results from its Phase 3 clinical trial (ACHIEVE-1) for orforglipron, which saw the stock increase by over 25%. The drug demonstrated improved gastrointestinal tolerability and significant enhancements in liver safety markers, with ALT and AST levels improving over time, which alleviated earlier concerns about liver safety. Additionally, orforglipron exhibited a favorable cardiovascular safety profile, further validating the company’s innovative approach in developing therapeutics targeting chronic diseases with unmet medical needs.

Bears say

Structure Therapeutics Inc is facing a challenging financial outlook, as it has incurred significant net losses expected to continue until at least commercialization, impacting investor confidence. The company's current enterprise value of approximately $410 million and a year-to-date share price decline of 20% indicate market skepticism regarding its pipeline potential, particularly for the diabetes and obesity markets. Moreover, despite positive data suggesting reduced safety risks with its lead candidate, aleniglipron, the comparative weight loss efficacy falling behind competitors may hinder the company's ability to secure necessary commercial partnerships to advance its objectives.

GPCR has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Buy based on their latest research and market trends.

According to 11 analysts, GPCR has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $95.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $95.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.